title: Retinoic acid posttranscriptionally up-regulates proteolipid protein gene expression in C6 glioma cells.
abstract: The proteolipid protein (PLP) gene codes for the major central nervous system myelin protein. We have studied the effects of different agents on the expression of the PLP gene in C6 glioma cells. Retinoic acid (RA), but not dexamethasone, estradiol, insulin, growth hormone, or vitamin D3, had a drastic effect, increasing 10-20-fold the level of PLP mRNA. Concomitantly, RA also induced the appearance of the corresponding immunoreactive protein. The increase in PLP RNA level showed a slow kinetics and was blocked by cycloheximide, suggesting a posttranscriptional regulation by RA. Nuclear run-on assays confirmed that the rate of PLP gene transcription was unchanged by RA. In contrast, we found that retinoic acid augmented PLP mRNA stability, causing a substantial increase in its half-life. RA action was independent of cell density, serum, or PDGF but was partially inhibited by bFGF. On the other hand, thyroid hormone caused a moderate increase in PLP mRNA levels in C6 cells but only when the low numbers of thyroid receptors in these cells were increased by retrovirally mediated expression of an exogenous c-erbA/TR alpha-1 gene. Our results indicate that RA specifically up-regulates PLP expression in glioma C6 cells at a posttranscriptional level by increasing PLP RNA half-life.
authors.affiliation: Departamento de Investigación, Antibióticos-Farma S.A., Madrid, Spain.
authors.forename: M
authors.initials: M
authors.lastname: López-Barahona
authors.forename: M
authors.initials: M
authors.lastname: Miñano
authors.forename: E
authors.initials: E
authors.lastname: Mira
authors.forename: T
authors.initials: T
authors.lastname: Iglesias
authors.forename: H G
authors.initials: HG
authors.lastname: Stunnenberg
authors.forename: A
authors.initials: A
authors.lastname: Rodríguez-Peña
authors.forename: J
authors.initials: J
authors.lastname: Bernal
authors.forename: A
authors.initials: A
authors.lastname: Muñoz
mesh_terms: D000818:Animals; D002117:Calcitriol / Q000494:pharmacology; D002455:Cell Division; D002460:Cell Line; D002467:Cell Nucleus / Q000378:metabolism; D003907:Dexamethasone / Q000494:pharmacology; D004958:Estradiol / Q000494:pharmacology; D016222:Fibroblast Growth Factor 2 / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects*; D005910:Glioma; D013006:Growth Hormone / Q000494:pharmacology; D006801:Humans; D007700:Kinetics; D009185:Myelin Proteins / Q000032:analysis / Q000096:biosynthesis*; D018991:Myelin Proteolipid Protein; D010982:Platelet-Derived Growth Factor / Q000494:pharmacology; D011061:Poly A / Q000302:isolation & purification / Q000378:metabolism; D012313:RNA / Q000302:isolation & purification / Q000378:metabolism; D012333:RNA, Messenger / Q000096:biosynthesis* / Q000378:metabolism; D011988:Receptors, Thyroid Hormone / Q000096:biosynthesis; D014158:Transcription, Genetic; D014162:Transfection; D014212:Tretinoin / Q000494:pharmacology*; D014407:Tumor Cells, Cultured
chemical_list: D009185:Myelin Proteins; D018991:Myelin Proteolipid Protein; D010982:Platelet-Derived Growth Factor; D012333:RNA, Messenger; D011988:Receptors, Thyroid Hormone; D016222:Fibroblast Growth Factor 2; D011061:Poly A; D004958:Estradiol; D014212:Tretinoin; D012313:RNA; D003907:Dexamethasone; D013006:Growth Hormone; D002117:Calcitriol